134 related articles for article (PubMed ID: 15619007)
1. Cisplatin-induced genes as potential markers for thyroid cancer.
Lapouge G; Millon R; Muller D; Abecassis J; Eber M; Bergerat JP; Klein-Soyer C
Cell Mol Life Sci; 2005 Jan; 62(1):53-64. PubMed ID: 15619007
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function.
Céraline J; Deplanque G; Noël F; Natarajan-Amé S; Bergerat JP; Klein-Soyer C
Cancer Chemother Pharmacol; 2003 Jan; 51(1):91-5. PubMed ID: 12497212
[TBL] [Abstract][Full Text] [Related]
3. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
5. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.
Narimatsu M; Nagayama Y; Akino K; Yasuda M; Yamamoto T; Yang TT; Ohtsuru A; Namba H; Yamashita S; Ayabe H; Niwa M
J Clin Endocrinol Metab; 1998 Oct; 83(10):3668-72. PubMed ID: 9768682
[TBL] [Abstract][Full Text] [Related]
7. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
[TBL] [Abstract][Full Text] [Related]
8. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
10. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract][Full Text] [Related]
11. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
12. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
Fajac A; Da Silva J; Ahomadegbe JC; Rateau JG; Bernaudin JF; Riou G; Bénard J
Int J Cancer; 1996 Sep; 68(1):67-74. PubMed ID: 8895543
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function.
Dorigo O; Turla ST; Lebedeva S; Gjerset RA
J Neurosurg; 1998 Mar; 88(3):535-40. PubMed ID: 9488309
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
17. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma.
Kerley-Hamilton JS; Pike AM; Li N; DiRenzo J; Spinella MJ
Oncogene; 2005 Sep; 24(40):6090-100. PubMed ID: 15940259
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
19. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.
Matias-Guiu X; Cuatrecasas M; Musulen E; Prat J
J Clin Pathol; 1994 Apr; 47(4):337-9. PubMed ID: 8027371
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]